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Abstract
Background Data on immune checkpoint inhibitor efficacy in patients with human epidermal growth factor receptor 2-posi-
tive (HER2+) advanced gastric/gastroesophageal junction (G/GEJ) cancer are lacking. Because HER2 status was not captured 
in the ATT RAC TION-2 trial, we used patients with prior trastuzumab use (Tmab+) as surrogate for HER2 expression status 
to evaluate the efficacy and safety of nivolumab as third- or later-line therapy in these patients.
Methods In ATT RAC TION-2, a randomized, double-blind, placebo-controlled, phase 3 multicenter trial, patients were 
randomized (2:1) to receive nivolumab (3 mg/kg) or placebo every 2 weeks until disease progression or toxicity requiring 
study discontinuation. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety 
were assessed.
Results Of 493 enrolled patients, 81 (nivolumab, n = 59; placebo, n = 22) were Tmab+ and 412 (nivolumab, n = 271; placebo, 
n = 141) were Tmab−. In both groups, patients receiving nivolumab showed a longer median OS vs placebo (Tmab+, 8.3 
[95% confidence interval, 5.3–12.9] vs 3.1 [1.9–5.3] months, hazard ratio, 0.38 [0.22–0.66]; P = 0.0006; Tmab−, 4.8 [4.1–6.0] 
vs 4.2 [3.6–4.9] months, 0.71 [0.57–0.88]; P = 0.0022). PFS was longer in both groups receiving nivolumab vs placebo 
(Tmab+, 1.6 [1.5–4.0] vs 1.5 [1.3–2.9] months, 0.49 [0.29–0.85]; P = 0.0111; Tmab−, 1.6 [1.5–2.4] vs 1.5 [1.5–1.5] months, 
0.64 [0.51–0.80]; P = 0.0001).
Conclusions Nivolumab was efficacious and safe as third- or later-line therapy regardless of prior trastuzumab use in patients 
with advanced G/GEJ cancer.
Keywords Nivolumab · Gastric cancer · Gastroesophageal junction cancer · Trastuzumab
Introduction
Gastric/gastroesophageal junction (G/GEJ) cancer is the fifth 
most common cancer and the third leading cause of can-
cer-related deaths globally, according to the World Health 
Organization’s latest estimates [1]. Nearly 1 million new 
cases and ~ 725,000 deaths attributable to G/GEJ cancer 
occurred in 2012, with the highest incidence and mortality 
rates reported in East Asia [1].
First-line standard of care in patients with human epider-
mal growth factor receptor 2-negative (HER2−), unresect-
able, or recurrent G/GEJ cancer includes a two-drug combi-
nation of platinum-based agents and fluoropyrimidines, e.g., 
cisplatin, oxaliplatin, S-1, capecitabine, or 5-fluorouracil. In 
some medically fit patients with good performance status, 
a third drug, e.g., docetaxel or epirubicin, may be added [2-
4]. Depending on the method of assessment, ~ 6 to ~ 37% 
of all G/GEJ cancers show HER2 overexpression [5, 6]. 
Based on the results of the ToGA study [7], trastuzumab is 
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now recommended in combination with chemotherapy as 
first-line therapy in patients with HER2-positive (HER2+) 
metastatic or advanced G/GEJ cancer [2-4].
While trastuzumab showed a survival benefit as first-line 
chemotherapy for HER2+ G/GEJ cancer patients in the 
ToGA study, none of the other anti-HER2 drugs, such as 
lapatinib or trastuzumab–emtansine (T-DM1), or continu-
ing trastuzumab beyond progression in second-line treat-
ment showed benefits [8-10]. Recently, studies evaluat-
ing trastuzumab resistance mechanisms have highlighted 
certain pathways for resistance. In the multicenter, pro-
spective, case–control AMNESIA study in patients with 
HER2+ metastatic gastric cancer, genomic alterations in 
the epidermal growth factor receptor (EGFR)/MET/KRAS/
PI3K/PTEN pathway were significantly more frequent in 
trastuzumab-resistant (55%) patients than in trastuzumab-
sensitive (0%) patients, and patients without these genomic 
alterations had a significantly longer median progression-
free survival (PFS) (5.2 vs 2.6 months, hazard ratio [HR], 
0.34 [95% confidence interval (CI), 0.07–0.48]; P = 0.001) 
and overall survival (OS) (16.1 vs 7.6 months; HR, 0.38 
[95% CI 0.09–0.75]; P = 0.015) than those with alterations 
[11]. At present, however, no chemotherapy regimen specific 
to HER2+ G/GEJ cancer patients has been established in the 
second- or later-line treatment setting.
In the ATT RAC TION-2 trial [12], nivolumab, an anti-
programmed death-1 (PD-1) immunoglobulin G4 anti-
body, demonstrated significant survival benefits compared 
with placebo as the salvage-line treatment for patients 
with advanced G/GEJ cancer who were previously treated 
with ≥ 2 chemotherapy regimens (median OS: nivolumab, 
5.26 months [95% CI 4.60–6.37]; placebo, 4.14 months 
[3.42–4.86]; HR 0.63 [0.51–0.78]; P < 0.0001). In Japan, 
nivolumab monotherapy is recommended as third-line treat-
ment after the results of the ATT RAC TION-2 study demon-
strated its efficacy [13], whereas in the United States, pem-
brolizumab is recommended for third- or later-line treatment 
in patients with PD-ligand 1 (PD-L1+)  advanced G/GEJ 
cancer based on findings from the KEYNOTE-059 study 
[14] regardless of prior chemotherapy regimens.
The relationship between HER2 and PD-L1 expres-
sion has been assessed in a few studies recently; however, 
there are conflicting conclusions regarding their correlation 
[15-18]. In a study evaluating the expression and impact 
of PD-L1/PD-1 in gastric cancer in Caucasian patients, 
almost 50% of PD-L1+ patients were HER2+ [15]. In 
in vitro studies in HER2-overexpressing cell lines, PD-L1 
expression decreased in a dose- and time-dependent manner 
after EGFR/HER2-targeted treatment [17]. In contrast, in a 
retrospective analysis of resected, treatment-naïve gastric 
cancers, PD-L1 expression was observed more frequently 
in the HER2 − group than in the HER2+ group (39.0% vs 
24.2%; P = 0.020) [18]. Thus, discrepancies concerning the 
relationship between HER2 and PD-L1 expression exist and 
data related to the combined or sequential use of anti-HER2 
and anti–PD-1/PD-L1 agents are also lacking. In the ATT 
RAC TION-2 trial, we did not observe a clear relationship 
between PD-L1 expression and efficacy of nivolumab; fur-
thermore, there is no evidence in literature regarding the 
outcome of immune checkpoint inhibitor treatment, includ-
ing nivolumab, on HER2+ patients. Although HER2 status 
was not captured in ATT RAC TION-2, the study did include 
patients who had previously used or not used trastuzumab. 
Therefore, exploratory analysis of ATT RAC TION-2 data 
based on prior trastuzumab-use status could serve as sur-
rogate for HER2 expression status.
The objective of this post hoc analysis of the ATT 
RAC TION-2 trial was to assess the efficacy and safety of 
nivolumab for advanced G/GEJ cancer in patients who had 
previously used trastuzumab.
Methods
Study design
In this post hoc analysis of the ATT RAC TION-2 trial [12], 
a randomized, double-blind, placebo-controlled, phase 3 
trial conducted at 49 sites in Japan, South Korea, and Tai-
wan between October 2014 and August 2016, the efficacy 
and safety of nivolumab were studied according to previ-
ous use of trastuzumab. ATT RAC TION-2 (ClinicalTrials.
gov ID: NCT02267343) was conducted in accordance with 
the Declaration of Helsinki and the Good Clinical Practice 
guidelines developed by the International Conference on 
Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use [19]. The protocol was 
approved by the institutional review board or independent 
ethics committee for each study center. Written informed 
consent was obtained from all patients.
Patients
Patients were eligible if they were aged ≥ 20 years, had 
unresectable or metastatic, histologically confirmed G/GEJ 
adenocarcinoma, were treated with ≥ 2 previous chemother-
apy regimens, were refractory to or intolerant of standard 
therapy in the advanced or recurrent setting, had not planned 
to receive new chemotherapy including antibodies, had an 
Eastern Cooperative Oncology Group performance status 
of 0 or 1, and had a life expectancy of ≥ 3 months. Patients 
were excluded if they had an ongoing or previous autoim-
mune or interstitial lung disease; active diverticulitis or 
gastrointestinal ulcerative disease, or other uncontrolled or 
clinically significant medical disorder; brain metastases that 
were symptomatic or required treatment; and had previously 
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been treated with anti-PD-1, anti-PD-L1 or anti-PD-L2, anti-
CD137, or anti-CTLA-4 antibodies.
Treatment
Enrolled patients were randomized in a 2:1 ratio via an inter-
active web response system to receive nivolumab or placebo. 
Patients received 3 mg/kg nivolumab or placebo intrave-
nously every 2 weeks for 6 weeks (one treatment cycle). 
Dose modification was allowed in case of a ≥ 10% change 
in body weight after randomization. Study treatment was 
continued until progressive disease (PD) evaluated by an 
investigator or onset of toxicity requiring permanent discon-
tinuation of study treatment. Patients could continue study 
treatment after the first episode of PD if they showed evi-
dence of investigator-assessed clinical benefit, tolerance of 
study drug, and stable performance status; if continuation of 
treatment would not delay an intervention to prevent seri-
ous complications of disease progression; and if the patient 
provided written informed consent before continuing the 
study treatment.
Endpoints
The primary endpoint was OS. Secondary efficacy endpoints 
included PFS, objective response rate (ORR; proportion of 
patients with confirmed complete response [CR] or partial 
response [PR]), disease control rate (DCR; proportion of 
patients with confirmed CR, PR, or stable disease), duration 
of response (DOR), time to response (TTR), best overall 
response (BOR), and maximum percentage change from 
baseline in the sum of diameters of target lesions. Safety 
endpoints included adverse events (AEs) and treatment-
related AEs occurring through the study period.
Assessments
Tumor responses were assessed via computed tomogra-
phy or magnetic resonance imaging according to Response 
Evaluation Criteria In Solid Tumors guidelines version 
1.1. Tumor assessment was repeated after each cycle for 
ten cycles ( ~ 14 months), then after every two treatment 
cycles until discontinuation of study treatment because of 
PD, initiation of post-study treatment, or assessment of PD 
in patients who discontinued because of toxicity. Tumor 
assessments were also performed at the end of treatment. 
AEs were evaluated according to the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events version 4.0 continuously during treatment and for 
28 days thereafter. For patients with available tumor sam-
ples, PD-L1 tumor expression was determined retrospec-
tively by immunohistochemistry performed at a central 
laboratory (28-8 pharmDx assay; Dako, Carpinteria, CA, 
USA). PD-L1 positivity was defined as staining in ≥ 1% 
of tumor cells.
Statistical analysis
A subgroup analysis by history of trastuzumab use was 
conducted. The Kaplan–Meier method was used to esti-
mate the median OS, PFS, and the 95% CI for each treat-
ment group and subgroup. HRs between treatment groups 
and their 95% CIs were calculated using the Cox propor-
tional hazards model adjusted by demographic factors 
selected by a stepwise method for each subgroup. The P 
value of the HR was reported for the descriptive analysis 
of the difference between the two treatment groups. The 
P value of interaction term is reported for the model with 
both Tmab+ and Tmab− groups to evaluate association 
of Tmab use and treatment group. ORR and DCR, and 
their 95% CIs were estimated for each treatment group. 
Safety analyses were performed in the safety population 
(all patients who received at least one dose of study treat-
ment). SAS software (versions 9.3 and 9.4) was used for 
statistical analyses.
Results
Demographics and baseline characteristics
Overall, 81 patients (nivolumab, n = 59; placebo, n = 22) had 
a history of trastuzumab use (Tmab+) and 412 (nivolumab, 
n = 271; placebo, n = 141) had no history of trastuzumab 
use (Tmab−) (Fig. 1). Demographic and baseline charac-
teristics were mostly comparable between patients receiving 
nivolumab and placebo in both Tmab+ and Tmab− groups. 
Median age (range) was 62.0 (23.0–83.0) years in patients 
receiving nivolumab vs 62.5 (33.0–77.0) years in those 
receiving placebo in the Tmab+ group and 62.0 (20.0–83.0) 
vs 61.0 (26.0–83.0) years in the Tmab− group, respectively 
(Table 1). Among the four subgroups, the group of Tmab+ 
patients receiving nivolumab had a considerably lower 
proportion of patients with peritoneal metastasis (5/59 
[8.5%]). More patients in the Tmab+ groups (nivolumab, 
30/59 [50.8%]; placebo, 13/22 [59.1%]) had a history of 
four or more previous treatment regimens than those in 
the Tmab− groups (nivolumab, 94/271 [34.7%]; placebo, 
59/141 [41.8%]). Notably, previous ramucirumab use was 
more frequent in the Tmab+ group compared with the 
Tmab− group (Tmab+: nivolumab, 9/59 [15.3%]; placebo, 
4/22 [18.2%] and Tmab−: nivolumab, 26/271 [9.6%]; pla-
cebo, 18/141 [12.8%]). 
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Efficacy
In both Tmab+ and Tmab− groups, OS was longer in 
patients receiving nivolumab vs placebo (median [95% 
CI] OS: Tmab+ group, 8.3 [5.3–12.9] vs 3.1 [1.9–5.3] 
months, HR [95% CI], 0.38 [0.22–0.66]; P = 0.0006 and 
Tmab−  group, 4.8 [4.1–6.0] vs 4.2 [3.6–4.9] months, HR 
[95% CI], 0.71 [0.57–0.88]; P = 0.0022). The P interaction 
test for the association of trastuzumab use vs nivolumab with 
OS was significant (P = 0.0431) (Table 2). Survival curves 
for OS showed a consistent advantage with nivolumab vs 
placebo in both Tmab +  and Tmab−  patients (Fig. 2a, b). 
Benefit of nivolumab for PFS was also comparable in 
both Tmab +  and Tmab−  groups (median [95% CI] PFS: 
Tmab +  group, 1.6 [1.5–4.0] vs 1.5 [1.3–2.9] months, HR 
[95% CI], 0.49 [0.29–0.85]; P = 0.0111 and Tmab−  group, 
1.6 [1.5–2.4] vs 1.5 [1.5–1.5 months], HR [95% CI], 0.64 
[0.51–0.80]; P = 0.0001). The P interaction test for the asso-
ciation of trastuzumab use vs nivolumab with PFS was not 
significant (P = 0.3046) (Table 2). Notably, median PFS with 
nivolumab was similar in the Tmab+ and Tmab− groups. 
Kaplan–Meier curves for PFS of nivolumab and placebo 
initially overlapped in both Tmab+ and Tmab− groups but 
separated later (Fig. 2c, d).
ORR of patients receiving nivolumab was 16.9% in 
the Tmab+ group and 7.7% in the Tmab− group. None 
of the patients receiving placebo in either group showed 
any response (Table  2). A higher DCR was observed 
in patients receiving nivolumab than in those receiving 
placebo, irrespective of Tmab status (Tmab+, 42.4% vs 
31.8%; Tmab−, 30.6% vs 18.4%) (Table 2). Median (range) 
TTR was 3.0 (1.4–7.0) months and 1.6 (1.4–6.2) months in 
the Tmab+ and Tmab− groups receiving nivolumab, respec-
tively (Table 2). Median (range) DOR was 8.6 (4.3–13.1) 
months and 9.5 (2.8–22.9) months in the  Tmab+ and 
Tmab− groups receiving nivolumab, respectively.
The proportion of patients showing some tumor shrink-
age (> 1%) was higher in the nivolumab group than in the 
placebo group in both Tmab+ and Tmab− groups (Tmab+, 
38.8% vs 16.7%; Tmab−, 36.4% vs 10.5%).
Safety
Overall, incidence of any AE in patients receiving 
nivolumab was comparable between the  Tmab+ and 
Tmab− groups (54 [91.5%] vs 247 [91.1%]) (Online 
resource 1: Table). Incidence of any treatment-related AE 
in patients receiving nivolumab was slightly higher in the 
Tmab+ group than in the Tmab− group (31 [52.5%] vs 
111 [41.0%]), whereas the incidence of treatment-related 
serious AEs was comparable (6 [10.2%] vs 29 [10.7%]). 
The most frequent (≥ 10% in any group) treatment-related 
AEs among patients receiving nivolumab in the Tmab+ 
and Tmab− groups were pruritus (15.3% and 7.7%, respec-
tively) and rash (13.6% and 4.8%, respectively) (Table 3). 
Treatment-related AEs of special interest (frequency ≥ 2% 
in any group) in the Tmab+ and Tmab− groups included 
interstitial lung disease (3.4% and 1.5%, respectively) and 
Patients screened
N = 601
Patients enrolled
N = 493
Nivolumab 
(ITT population)
n = 330
Ineligible patients
Withdrew from study.............................n = 21
Did not meet inclusion criteria..............n = 37
Met exclusion criteria............................n = 42
Failed to return to study site.................n = 2
Other reasons.......................................n = 6
Placebo
(ITT population)
n = 163
Randomization
Tmab+
(ITT population)
n = 59
Tmab−
(ITT population)
n = 271
Tmab+
(Safety population)
n = 59
Tmab−
(Safety population)
n = 271
Tmab+
(Response assessment
population)
n = 53
Tmab−
(Response assessment
population)
n = 215
Tmab+
(ITT population)
n = 22
Tmab−
(ITT population)
n = 141
Tmab+
(Safety population)
n = 22
Tmab−
(Safety population)
n = 139
Tmab+
(Response assessment
population)
n = 20
Tmab−
(Response assessment
population)
n = 111 
Did not receive placebo
Patient request.........................n = 1
Did not meet enrollment criteria..n = 1
Fig. 1  Patient disposition. ITT intent to treat, Tmab trastuzumab
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Table 1  Patient demographic 
and baseline characteristics Tmab+ Tmab−
Nivolumab
n = 59
Placebo
n = 22
Nivolumab
n = 271
Placebo
n = 141
Sex
 Male 47 (79.7) 20 (90.9) 182 (67.2) 99 (70.2)
 Female 12 (20.3) 2 (9.1) 89 (32.8) 42 (29.8)
Age (years), median (range) 62 (23–83) 62.5 (33–77) 62 (20–83) 61 (26–83)
 < 65 35 (59.3) 12 (54.5) 154 (56.8) 83 (58.9)
Country
 Japan 31 (52.5) 12 (54.5) 121 (44.6) 62 (44.0)
 Korea 25 (42.4) 10 (45.5) 121 (44.6) 64 (45.4)
 Taiwan 3 (5.1) 0 29 (10.7) 15 (10.6)
ECOG performance status
 0 19 (32.2) 9 (40.9) 69 (25.5) 38 (27.0)
 1 40 (67.8) 13 (59.1) 202 (74.5) 103 (73.0)
Organs with metastases
 < 2 16 (27.1) 3 (13.6) 71 (26.2) 35 (24.8)
 ≥ 2 43 (72.9) 19 (86.4) 200 (73.8) 106 (75.2)
Site of metastases
 Lymph node 49 (83.1) 18 (81.8) 236 (87.1) 120 (85.1)
 Peritoneum 5 (8.5) 8 (36.4) 58 (21.4) 34 (24.1)
 Liver 16 (27.1) 4 (18.2) 62 (22.9) 24 (17.0)
 Lung 8 (13.6) 1 (4.5) 10 (3.7) 5 (3.5)
 Pleura 1 (1.7) 1 (4.5) 3 (1.1) 1 (0.7)
 Adrenal 2 (3.4) 1 (4.5) 4 (1.5) 3 (2.1)
 Bone 1 (1.7) 2 (9.1) 5 (1.8) 3 (2.1)
 Other 6 (10.2) 1 (4.5) 30 (11.1) 16 (11.3)
Number of previous chemotherapy regimens
 2 14 (23.7) 2 (9.1) 55 (20.3) 27 (19.1)
 3 15 (25.4) 7 (31.8) 122 (45.0) 55 (39.0)
 ≥ 4 30 (50.8) 13 (59.1) 94 (34.7) 59 (41.8)
Previous chemotherapy
 Any 59 (100) 22 (100) 271 (100) 141 (100)
 Pyrimidine analogs 59 (100) 22 (100) 270 (99.6) 141 (100)
 Platinum 59 (100) 22 (100) 252 (93.0) 135 (95.7)
 Taxane 53 (89.8) 19 (86.4) 231 (85.2) 121 (85.8)
 Irinotecan 42 (71.2) 18 (81.8) 205 (75.6) 105 (74.5)
 Ramucirumab 9 (15.3) 4 (18.2) 26 (9.6) 18 (12.8)
Previous gastrectomy
 No 23 (39.0) 8 (36.4) 94 (34.7) 43 (30.5)
 Yes 36 (61.0) 14 (63.6) 177 (65.3) 98 (69.5)
Any post-progression therapy
 Radiotherapy 4 (6.8) 0 24 (8.9) 16 (11.3)
 Surgery 8 (13.6) 2 (9.1) 59 (21.8) 26 (18.4)
 Pharmacotherapy 26 (44.1) 6 (27.3) 102 (37.6) 51 (36.2)
Post-progression pharmacotherapy
 Fluoropyrimidine 12 (20.3) 4 (18.2) 31 (11.4) 20 (14.2)
 Taxane 9 (15.3) 2 (9.1) 24 (8.9) 14 (9.9)
 Platinum 7 (11.9) 3 (13.6) 23 (8.5) 14 (9.9)
 Irinotecan 4 (6.8) 1 (4.5) 10 (3.7) 8 (5.7)
 Ramucirumab 10 (16.9) 1 (4.5) 29 (10.7) 11 (7.8)
 Immunotherapy 1 (1.7) 0 2 (0.7) 1 (0.7)
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maculopapular rash (5.1% and 0%, respectively). Among 
the patients receiving nivolumab, treatment-related AEs 
leading to discontinuation of treatment were reported 
in 3 (5.1%) and 6 (2.2%) patients, and those leading to 
delayed dosing were reported in 7 (11.9%) and 22 (8.1%) 
patients in the Tmab+ and Tmab− groups, respectively. 
Treatment-related death was reported in one (1.7%) and 
eight (3.0%) patients in the Tmab+ and Tmab− groups 
receiving nivolumab, respectively.
Discussion
In this post hoc analysis, nivolumab improved OS, 
PFS, ORR, DCR, and reduction in tumor burden com-
pared with placebo in both Tmab+ and Tmab− groups. 
Patients treated with nivolumab had a sustained and dura-
ble response compared with placebo in both Tmab+ and 
Tmab− groups. Safety of nivolumab was comparable 
between Tmab+ and Tmab− patients.
Table 1  (continued) Tmab+ Tmab−
Nivolumab
n = 59
Placebo
n = 22
Nivolumab
n = 271
Placebo
n = 141
 Other targeted therapies 1 (1.7) 0 5 (1.8) 5 (3.5)
PD-L1 status (tumor cell) (%)
 ≥ 1 2 (6.5)a 2 (13.3)b 14 (14.1)c 8 (17.0)d
 < 1 29 (93.5)a 13 (86.7)b 85 (85.9)c 39 (83.0)d
Data expressed as n (%) unless otherwise specified
ECOG Eastern Cooperative Oncology Group, Tmab trastuzumab, PD-L1 programmed death-ligand 1
a n = 31; bn = 15; cn = 99; dn = 47
Table 2  Efficacy analysis of 
nivolumab by previous use of 
trastuzumab
BOR best overall response, CI confidence interval, DCR disease control rate, DOR duration of response, 
HR hazard ratio, ORR objective response rate, OS overall survival, PD progressive disease, PFS progres-
sion-free survival, PR partial response, SD stable disease, Tmab trastuzumab, TTR time to response
a Adjustment factors: Tmab+, post-progression therapy surgery; Tmab−, organs with metastases (< 2), age 
(< 65 years), and recurrence site (peritoneum)
b P interaction represents the association of Tmab use vs nivolumab with OS or PFS
c Adjustment factors: Tmab+, organs with metastases (< 2); Tmab−, age (< 65 years) and recurrence site 
(liver)
Tmab+ Tmab−
Nivolumab
n = 59
Placebo
n = 22
Nivolumab
n = 271
Placebo
n = 141
BOR, n (%)
 PR 10 (16.9) 0 21 (7.7) 0
 SD 15 (25.4) 7 (31.8) 62 (22.9) 26 (18.4)
 PD 23 (39.0) 10 (45.5) 101 (37.3) 69 (48.9)
 NE 11 (18.6) 5 (22.7) 87 (32.1) 44 (31.2)
ORR, n (%)a 10 (16.9) 0 21 (7.7) 0
DCR, n (%)a 25 (42.4) 7 (31.8) 83 (30.6) 26 (18.4)
OS (months), median (95% CI) 8.3 (5.3–12.9) 3.1 (1.9–5.3) 4.8 (4.1–6.0) 4.2 (3.6–4.9)
 HR (95% CI)a 0.38 (0.22–0.66) 0.71 (0.57–0.88)
P value 0.0006 0.0022
P interaction, P  valueb 0.0431
PFS (months), median (95% CI) 1.6 (1.5–4.0) 1.5 (1.3–2.9) 1.6 (1.5–2.4) 1.5 (1.5–1.5)
 HR (95% CI)c 0.49 (0.29–0.85) 0.64 (0.51–0.80)
P value 0.0111 0.0001
P interaction, P  valueb 0.3046
DOR (months), median (range) 8.6 (4.3–13.1) – 9.5 (2.8–22.9) –
TTR (months), median (range) 3.0 (1.4–7.0) – 1.6 (1.4–6.2) –
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Trastuzumab in combination with platinum-based chemo-
therapy is the standard first-line treatment in HER2+ gas-
tric cancer patients [2-4] based on results from ToGA [7]. 
Although clinical trials using new anti-HER2 agents were 
successful for metastatic breast cancer, the results from pre-
vious studies conducted in the first- or second-line setting 
for HER2+ gastric cancer patients, however, were disap-
pointing. As the first-line palliative chemotherapy treat-
ment in the phase 3 trial (TRIO-013/LOGiC), patients with 
HER2+ advanced G/GEJ cancer received lapatinib (an anti-
HER2 agent) or placebo in combination with capecitabine 
plus oxaliplatin (CapeOX); OS was not significantly differ-
ent (median OS, 12.2 vs 10.5 months; HR, 0.91 [95% CI 
0.73–1.12]; P = 0.3492) [20]. Moreover, in a phase 3 trial 
(JACOB), metastatic G/GEJ cancer patients received per-
tuzumab (another anti-HER2 antibody) or placebo in com-
bination with trastuzumab plus chemotherapy (standard 
cisplatin/fluoropyrimidine regimen) as first-line treatment; 
OS was not significantly different between the pertuzumab 
and placebo arms (median OS, 17.5 vs 14.2 months; HR, 
0.84 [95% CI 0.71–1.00]; P = 0.0565) [21]. As the second-
line treatment in a randomized phase 2 study conducted by 
the West Japan Oncology Group (WJOG7112G [T-ACT]), 
trastuzumab plus paclitaxel showed no benefit over pacli-
taxel alone in patients with HER2+ advanced G/GEJ cancer 
refractory to first-line trastuzumab plus chemotherapy [8]. 
Development of new active agents for HER2+ G/GEJ cancer 
is warranted.
Nivolumab is recommended as a third-line or later-line 
therapy in gastric cancer patients who are likely to have 
received trastuzumab. Previous reports are suggestive of 
the impact of anti-HER2 therapy on the expression of 
PD-L1 [15-18] and of the decrease in HER2 expression 
in some patients during treatment with trastuzumab [22, 
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Fig. 2  Kaplan–Meier plot of overall survival in a Tmab+ and b Tmab− patients and progression-free survival in c Tmab+ and d Tmab− 
patients. CI confidence interval, ITT intent to treat, Tmab trastuzumab
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23]. It was thus hypothesized that HER2 expression and/
or prior use of trastuzumab might have had some influence 
on the efficacy of nivolumab in the ATT RAC TION-2 trial. 
In this analysis, nivolumab showed similar efficacy regard-
less of prior trastuzumab use. However, the HR for OS 
was better in the Tmab+ group than in the Tmab− group 
(interaction P = 0.0431). Apart from prior trastuzumab 
use, the proportion of patients receiving post-progression 
pharmacotherapy was slightly higher in the Tmab+ group 
treated with nivolumab. Because OS is affected by many 
other factors, including the patient’s background and post-
progression pharmacotherapy, the efficacy of nivolumab 
is best represented by the response rate and PFS. In terms 
of HR for PFS, no difference was observed between the 
Tmab+ and Tmab− groups (interaction P = 0.3046). 
Therefore, it could not be deduced that nivolumab showed 
better efficacy in HER2+ G/GEJ cancer patients. To say 
the least, the results of this study suggest that nivolumab 
can be efficacious regardless of HER2 expression status.
Also, considering the patient background, fewer 
patients receiving nivolumab had peritoneal metastases 
in the Tmab+ than in the Tmab− group (8.5% vs 21.4%, 
respectively). On the other hand, the proportion of patients 
receiving nivolumab who had received ≥ 4 previous treat-
ment regimens was higher in the Tmab+ group compared 
with the Tmab− group (50.8% vs 34.7%, respectively). 
Furthermore, 15.3% and 9.6% of patients receiving 
nivolumab in the Tmab+ and Tmab− groups, respectively, 
had been previously treated with ramucirumab. These dif-
ferences in prior chemotherapy suggest that fewer active 
agents were available after nivolumab for the Tmab+ 
group than the Tmab− group. Therefore, it is difficult 
to explain the longer OS in the Tmab+ group based on 
patient background alone.
As the relationship between HER2 and PD-L1 expression 
is still unknown, further investigation will be required to 
examine whether nivolumab provides longer survival benefit 
in HER2+ G/GEJ cancer and to elucidate the mechanisms 
involved.
The safety profile of nivolumab both in Tmab+ and 
Tmab− patients with advanced G/GEJ cancer was similar 
to that previously reported and known for nivolumab. Most 
AEs and treatment-related AEs were mild to moderate in 
severity; no unexpected AEs were observed.
There are certain limitations associated with this study. 
The number of HER2+ patients was small and associated 
with substantial differences in patient backgrounds. The 
HER2 status of patients immediately before enrollment and 
its change during treatment was not assessed. In addition, 
PD-L1 status was assessed using archival tissues before tras-
tuzumab use in a limited number of patients. Therefore, it is 
not clear whether trastuzumab treatment may have altered 
PD-L1 expression, just as lapatinib and afatinib have pre-
viously been shown to suppress PD-L1 expression via the 
EGFR/HER2 signaling blockade [17]. Although the higher 
proportion of patients receiving post-progression pharma-
cotherapy is one of the factors that could have contributed 
to the significantly longer OS in the Tmab+ group between 
nivolumab and placebo, we did not evaluate its influence 
on the OS.
Conclusions
The efficacy and safety of nivolumab for advanced G/GEJ 
cancer were consistent regardless of prior trastuzumab use. 
We anticipate the future development of anti-PD-1 agents 
including nivolumab for HER2+, advanced G/GEJ cancer.
Table 3  Safety analysis of nivolumab by previous use of trastuzumab
All data presented as n (%)
AE adverse event, ALT alanine aminotransferase, AST aspartate ami-
notransferase, Tmab trastuzumab
a Events that occurred in ≥ 2% of patients receiving nivolumab in the 
Tmab+ or Tmab− group
Tmab+ Tmab−
Nivolumab
n = 59
Placebo
n = 22
Nivolumab
n = 271
Placebo
n = 139
Common treatment-related  AEsa
 Pruritus 9 (15.3) 3 (13.6) 21 (7.7) 6 (4.3)
 Rash 8 (13.6) 1 (4.5) 13 (4.8) 4 (2.9)
 Diarrhea 4 (6.8) 0 19 (7.0) 3 (2.2)
 Malaise 3 (5.1) 0 10 (3.7) 6 (4.3)
 Nausea 3 (5.1) 0 12 (4.4) 4 (2.9)
 ALT increased 1 (1.7) 0 7 (2.6) 1 (0.7)
 AST increased 1 (1.7) 1 (4.5) 10 (3.7) 2 (1.4)
 Fatigue 1 (1.7) 2 (9.1) 17 (6.3) 7 (5.0)
 Hypothyroidism 1 (1.7) 0 10 (3.7) 1 (0.7)
 Decreased appetite 0 0 16 (5.9) 7 (5.0)
 Pyrexia 0 0 9 (3.3) 3 (2.2)
Treatment-related AEs of special interest
 Maculopapular rash 3 (5.1) 0 0 0
 Interstitial lung 
disease
2 (3.4) 0 4 (1.5) 0
 Hypopituitarism 1 (1.7) 0 0 0
 Hypothyroidism 1 (1.7) 0 10 (3.7) 1 (0.7)
 Acute hepatitis 0 0 1 (0.4) 0
 Autoimmune thy-
roiditis
0 0 1 (0.4) 0
 Colitis 0 0 2 (0.7) 0
 Hyperthyroidism 0 0 2 (0.7) 0
 Pneumonitis 0 0 1 (0.4) 0
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